These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34883037)

  • 41. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
    Boixeda D; Bermejo F; Martín-De-Argila C; López-Sanromán A; Defarges V; Hernández-Ranz F; Milicua JM; García-Plaza A
    Aliment Pharmacol Ther; 2002 Aug; 16(8):1457-60. PubMed ID: 12182745
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
    Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH
    Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
    Songür Y; Senol A; Balkarli A; Baştürk A; Cerçi S
    Am J Med Sci; 2009 Jul; 338(1):50-3. PubMed ID: 19474657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B; Wang J; Li J; Liu L; Chen Y
    Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial.
    Tsay FW; Wu DC; Kao SS; Tsai TJ; Lai KH; Cheng JS; Chan HH; Wang HM; Tsai WL; Tseng HH; Peng NJ; Hsu PI
    Helicobacter; 2015 Feb; 20(1):71-7. PubMed ID: 25495272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addition of bismuth to standard triple therapy for Helicobacter pylori eradication: a randomised controlled trial.
    Asim M; Baqai K; Abbas Z; Laique N; Samejo SA
    J Pak Med Assoc; 2020 Aug; 70(8):1334-1339. PubMed ID: 32794482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
    Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
    Valle Muñoz J; Muñoz Gómez P; Sierra Bernal C; de Andrés E; Gómez Hernando C; Gómez Rodríguez R
    Rev Esp Enferm Dig; 2019 Sep; 111(9):655-661. PubMed ID: 31345044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial.
    Kaviani MJ; Malekzadeh R; Vahedi H; Sotoudeh M; Kamalian N; Amini M; Massarrat S
    Eur J Gastroenterol Hepatol; 2001 Aug; 13(8):915-9. PubMed ID: 11507355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
    Ciccaglione AF; Cellini L; Grossi L; Marzio L
    World J Gastroenterol; 2012 Aug; 18(32):4386-90. PubMed ID: 22969203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
    Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
    Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication.
    Gisbert JP; Marcos S; Gisbert JL; Pajares JM
    Helicobacter; 2001 Jun; 6(2):157-62. PubMed ID: 11422472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
    Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for
    Kim BJ; Lee H; Lee YC; Jeon SW; Kim GH; Kim HS; Sung JK; Lee DH; Kim HU; Park MI; Choi IJ; Yoon SM; Kim SW; Baik GH; Lee JY; Kim JI; Kim SG; Kim J; Lee J; Kim JG; Kim JJ;
    Gut Liver; 2019 Sep; 13(5):531-540. PubMed ID: 31505907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea.
    Kim SY; Lee SW; Choe JW; Jung SW; Hyun JJ; Jung YK; Koo JS; Yim HJ
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28940815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Non-bismuth quadruple therapy versus standard triple therapy for Helicobacter pylori eradication: a randomized controlled study].
    Wang S; Wang W; Chu Y; Teng G; Hu F
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(8):576-9. PubMed ID: 24762684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.
    Georgopoulos SD; Ladas SD; Karatapanis S; Triantafyllou K; Spiliadi C; Mentis A; Artikis V; Raptis SA
    Aliment Pharmacol Ther; 2002 Mar; 16(3):569-75. PubMed ID: 11876712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.